The Novavax vaccine being developed for Covid-19 has been shown to be nearly 90% effective, and to also work against the UK and South African variants. The UK has bought 60m doses and it will be manufactured on Teesside. If given emergency authorisation it could help solve potential problems with supply of the two vaccines currently in use, from AstraZeneca and Pfizer. The Novavax shot gives some protection – though less, at 60% – against the South African variant. Novavax plans to design a vaccine specifically to work against the variant in South Africa, which scientists think may be capable of evading vaccines currently being administered.